Study in Healthy Volunteers to Examine the Safety, Tolerability and Plasma Pharmacokinetics of One Intramuscular (IM) Injection of a Novel TMC278 LA Formulation at 2 Different Doses (Open Label), Followed by a Placebo-controlled Part of Multiple IM Injections at a Selected Dose (Double Blind).

Trial Profile

Study in Healthy Volunteers to Examine the Safety, Tolerability and Plasma Pharmacokinetics of One Intramuscular (IM) Injection of a Novel TMC278 LA Formulation at 2 Different Doses (Open Label), Followed by a Placebo-controlled Part of Multiple IM Injections at a Selected Dose (Double Blind).

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Rilpivirine (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 12 Dec 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 12 Dec 2011 Actual initiation date changed from Feb 2010 to Jan 2010 as reported by ClinicalTrials.gov.
    • 12 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top